Literature DB >> 32414813

Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.

Giovanni Targher1, Alessandro Mantovani2, Christopher D Byrne3, Xiao-Bo Wang4, Hua-Dong Yan5, Qing-Feng Sun6, Ke-Hua Pan6, Kenneth I Zheng7, Yong-Ping Chen8, Mohammed Eslam9, Jacob George9, Ming-Hua Zheng10,11.   

Abstract

Entities:  

Keywords:  nonalcoholic steatohepatitis

Mesh：

Year:  2020        PMID： 32414813     DOI： 10.1136/gutjnl-2020-321611

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  66 in total

Review 1.  Impact of COVID-19 in Liver Disease Progression.

Authors:  Miguel Angel Martinez; Sandra Franco
Journal:  Hepatol Commun       Date:  2021-05-31

Review 2.  Global pandemics interconnected - obesity, impaired metabolic health and COVID-19.

Authors:  Norbert Stefan; Andreas L Birkenfeld; Matthias B Schulze
Journal:  Nat Rev Endocrinol       Date:  2021-01-21       Impact factor: 43.330

3.  The Impact of Increased Fib-4 Score in Patients with Type II Diabetes Mellitus on Covid-19 Disease Prognosis.

Authors:  Ovidiu P Calapod; Andreea M Marin; Minodora Onisai; Laura C Tribus; Corina S Pop; Carmen Fierbinteanu-Braticevici
Journal:  Medicina (Kaunas)       Date:  2021-04-30       Impact factor: 2.430

4.  Liver stiffness is associated with disease severity and worse clinical scenarios in coronavirus disease 2019: A prospective transient elastography study.

Authors:  Coskun Ozer Demirtas; Caglayan Keklikkiran; Ilkay Ergenc; Buket Erturk Sengel; Gunes Eskidemir; Ismail Cinel; Zekaver Odabasi; Volkan Korten; Yusuf Yilmaz
Journal:  Int J Clin Pract       Date:  2021-05-29       Impact factor: 3.149

Review 5.  COVID-19 in normal, diseased and transplanted liver.

Authors:  Alessandro Signorello; Ilaria Lenci; Martina Milana; Giuseppe Grassi; Leonardo Baiocchi
Journal:  World J Gastroenterol       Date:  2021-05-28       Impact factor: 5.742

Review 6.  Nonalcoholic fatty liver disease and COVID-19: An epidemic that begets pandemic.

Authors:  Musaab Ahmed; Mohamed H Ahmed
Journal:  World J Clin Cases       Date:  2021-06-16       Impact factor: 1.337

Review 7.  COVID-19 and pediatric fatty liver disease: Is there interplay?

Authors:  Anna Di Sessa; Francesca Lanzaro; Sarah Zarrilli; Vittorio Picone; Stefano Guarino; Emanuele Miraglia Del Giudice; Pierluigi Marzuillo
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742

8.  Radiographic Hepatic Steatosis Is Not Associated With Key Clinical Outcomes Among Patients Hospitalized With COVID-19.

Authors:  Hirsh D Trivedi; Robert Wilechansky; Daniela Goyes; Joana Vieira Barbosa; Andrew Canakis; Michelle Lai; Michelle T Long; Zachary Fricker
Journal:  Gastroenterology Res       Date:  2021-06-19

9.  Possible unrecognised liver injury is associated with mortality in critically ill COVID-19 patients.

Authors:  Mario Romero-Cristóbal; Ana Clemente-Sánchez; Patricia Piñeiro; Jamil Cedeño; Laura Rayón; Julia Del Río; Clara Ramos; Diego-Andrés Hernández; Miguel Cova; Aranzazu Caballero; Ignacio Garutti; Pablo García-Olivares; Javier Hortal; Jose-Eugenio Guerrero; Rita García; Rafael Bañares; Diego Rincón
Journal:  Therap Adv Gastroenterol       Date:  2021-06-14       Impact factor: 4.409

Review 10.  Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis.

Authors:  Donovan A McGrowder; Fabian Miller; Melisa Anderson Cross; Lennox Anderson-Jackson; Sophia Bryan; Lowell Dilworth
Journal:  Diseases       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.